See more : Synlait Milk Limited (SML.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of PTC Therapeutics, Inc. (PTCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Oriental Shiraishi Corporation (1786.T) Income Statement Analysis – Financial Results
- Summer Energy Holdings, Inc. (SUME) Income Statement Analysis – Financial Results
- CL Holdings Inc. (4286.T) Income Statement Analysis – Financial Results
- Black Hills Corporation (BKH) Income Statement Analysis – Financial Results
- Harrys Manufacturing Inc. (HARY.CN) Income Statement Analysis – Financial Results
PTC Therapeutics, Inc. (PTCT)
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.71M | 36.77M | 22.96M | 31.33M | 28.78M | 98.96M |
| Cost of Revenue | 65.49M | 44.68M | 32.33M | 18.94M | 12.14M | 12.67M | 4.58M | 117.63M | 121.82M | 79.84M | 54.88M | -5.17M | 0.00 |
| Gross Profit | 872.34M | 654.12M | 506.27M | 361.82M | 294.85M | 252.06M | 189.82M | -34.93M | -85.05M | -56.88M | -23.55M | 33.95M | 98.96M |
| Gross Profit Ratio | 93.02% | 93.61% | 94.00% | 95.03% | 96.05% | 95.21% | 97.65% | -42.23% | -231.33% | -247.68% | -75.17% | 117.95% | 100.00% |
| Research & Development | 666.56M | 651.50M | 540.68M | 477.64M | 257.45M | 171.98M | 117.46M | 117.63M | 121.82M | 79.84M | 54.88M | 46.14M | 58.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 332.54M | 326.00M | 285.77M | 245.16M | 202.54M | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Other Expenses | 0.00 | 116.55M | 54.75M | 36.89M | 27.65M | 129.00K | -1.28M | -1.21M | -465.00K | -213.00K | 37.51K | 1.78M | 461.36K |
| Operating Expenses | 1.31B | 1.09B | 881.21M | 759.70M | 487.64M | 348.41M | 254.11M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Cost & Expenses | 1.29B | 1.14B | 913.54M | 778.64M | 499.78M | 361.08M | 258.68M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Interest Income | 0.00 | 90.87M | 86.02M | 56.35M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 129.18M | 90.87M | 86.02M | 56.35M | 12.49M | 12.55M | 12.09M | 8.28M | 2.37M | 1.18M | 0.00 | 0.00 | 2.44M |
| Depreciation & Amortization | 236.59M | 128.84M | 71.52M | 49.58M | 36.06M | 26.09M | 17.68M | 3.29M | 2.88M | 2.24M | 2.40M | 2.70M | 2.87M |
| EBITDA | -330.34M | -367.78M | -374.44M | -297.00M | -191.38M | -89.47M | -46.61M | -128.77M | -164.25M | -97.18M | -43.00M | -24.10M | 33.45M |
| EBITDA Ratio | -35.22% | -53.32% | -70.20% | -59.83% | -38.04% | -20.45% | -25.16% | -159.67% | -454.58% | -432.93% | -136.85% | -83.76% | 33.80% |
| Operating Income | -349.40M | -439.93M | -374.94M | -397.88M | -192.80M | -115.69M | -64.29M | -132.06M | -167.13M | -99.41M | -45.40M | -26.81M | 30.58M |
| Operating Income Ratio | -37.26% | -62.95% | -69.62% | -104.49% | -62.80% | -43.70% | -33.07% | -159.67% | -454.58% | -432.93% | -144.92% | -93.15% | 30.90% |
| Total Other Income/Expenses | -346.71M | -147.56M | -143.40M | -59.36M | -47.13M | -12.43M | -13.37M | -9.48M | -2.83M | 967.00K | -6.18M | 573.00K | -1.98M |
| Income Before Tax | -696.11M | -587.49M | -518.34M | -402.93M | -239.93M | -128.11M | -77.67M | -141.54M | -169.96M | -98.45M | -51.57M | -26.24M | 28.60M |
| Income Before Tax Ratio | -74.23% | -84.07% | -96.24% | -105.82% | -78.16% | -48.39% | -39.95% | -171.14% | -462.28% | -428.72% | -164.63% | -91.16% | 28.90% |
| Income Tax Expense | -69.51M | -28.47M | 5.56M | 35.23M | 11.65M | -29.00K | 1.34M | 569.00K | 485.00K | -4.69M | 6.21M | 1.21M | -2.31M |
| Net Income | -626.60M | -559.02M | -523.90M | -438.16M | -251.58M | -128.08M | -79.00M | -142.11M | -170.45M | -93.75M | -51.57M | -26.24M | 30.90M |
| Net Income Ratio | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.60% | -408.28% | -164.63% | -91.16% | 31.23% |
| EPS | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.85 | 0.00 |
| EPS Diluted | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.11 | 0.00 |
| Weighted Avg Shares Out | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.11M | 34.04M | 33.62M | 31.57M | 12.82M | 14.19M | 14.19M |
| Weighted Avg Shares Out (Dil) | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 23.68M | 23.68M |
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
PTC Therapeutics to Participate at Upcoming Investor Conferences
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Source: https://incomestatements.info
Category: Stock Reports